ArticleScientific reports2025
The interventional role and mechanism of total flavonoids in lychee seeds on rats with liver fibrosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Elucidating the therapeutic mechanisms of quercetin in hepatic fibrosis: an integrated metabolomic and transcriptomic analysis.Frontiers in nutrition · 2026Article
- Mechanisms underlying the role of the oral-gut-liver axis in the promotion of liver fibrosis by periodontal disease: an interacting network of inflammation, microbiota, and barrier function.Frontiers in cellular and infection microbiology · 2026Review
- Fecal Zonulin as a Non-Invasive Marker of Intestinal Permeability: Findings from a Prospective Cohort Study.Medicina (Kaunas, Lithuania) · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
This study explored the interventional role and potential mechanism of total flavonoids from lychee seeds (TFL) on rats with liver fibrosis, focusing on the LPS/TLR2/4 signaling pathway and intestinal mucosal barrier theories. Male Sprague-Dawley (SD) rats were randomly divided into six groups: Control, Model, Silymarin (43.19 mg·kg⁻¹), TFL low dose (TFL-L, 25 mg·kg⁻¹), TFL medium dose (TFL-M, 50 mg·kg⁻¹), and TFL high dose (TFL-H, 100 mg·kg⁻¹). All groups received oral administration once daily for six weeks. Histopathological evaluations of liver tissues were conducted using HE and Masson staining, while fibrosis scores were assessed. Colon tissues were examined by HE staining for signs of inflammation and cellular infiltration. Immunohistochemistry detected the expression of tight junction proteins ZO-1, occludin, claudin 1, and claudin 4 related to the intestinal barrier. Serum levels of HA, IV-C, LN, PC-III, ALT, AST, and LPS were determined via ELISA. RT-qPCR was used to measure gene expression levels of TNF-α, IL-6, IL-1β, Ccl2, Ccl4, TLR2, TLR4 in liver tissue, and ZO-1, occludin, claudin 1, and claudin 4 in colon tissue. Compared to the Control group, the Model group exhibited significantly higher fibrosis scores, increased serum LPS, ALT, AST, LN, HA, IV-C, and PC-III levels, as well as elevated relative expression levels of Ccl2, TLR2, TLR4, IL-6, IL-1β, and TNF-α genes. After treatment with TFL, pathological scores in all TFL groups were significantly reduced, along with decreased serum levels of LPS, ALT, AST, HA, IV-C, and PC-III compared to the Model group. The relative expression levels of Ccl2, TLR2, TLR4, IL-1β, IL-6, and TNF-α genes in the TFL-H group were also notably lower than those in the Model group. No significant differences were observed in the relative expression of Ccl4 across groups. In addition, the expression of various tight junction-related proteins in the colonic mucosa of the Model group was significantly reduced, whereas the TFL-H group showed significantly richer staining compared to the Model group. TFL demonstrates a good anti-fibrotic effect, with a clear dose-response relationship, where the highest dosage produced the best results. Its anti-fibrotic effect may be associated with restoring intestinal mucosal barrier function and inhibiting the LPS/TLR2/4 signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.